Non-small cell lung cancer (NSCLC) presents persistent challenges in immunotherapy, as the clinical benefit of programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1) inhibitors is frequently constrained by intrinsic and acquired resistance. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.